Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy

被引：0
|
作者：
Schroeder, Mark A.
Fiala, Mark A.
Ghobadi, Armin
Stockerl-Goldstein, Keith E.
Wildes, Tanya M.
Vij, Ravi
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4335
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas
    Wang, Yong
    Chen, Yajing
    Geng, Hua
    Qi, Can
    Liu, Yunde
    Yue, Dan
    TUMOR BIOLOGY, 2015, 36 (09) : 7159 - 7166
  • [22] High EZH2 Protein Expression Is Associated with Inferior Survival in Patients with Multiple Myeloma
    Tremblay-LeMay, Rosemarie
    Pourabdollah, Maryam
    Rastgoo, Nasrin
    Chang, Hong
    MODERN PATHOLOGY, 2018, 31 : 560 - 561
  • [23] High-dose sequential chemotherapy in the treatment of myeloma
    Canales, M
    Ojeda, E
    Alvárez, MT
    Jiménez, V
    Jiménez, MT
    Hernández, D
    Aguado, MJ
    Bustos, JG
    Hernández-Navarro, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 352 - 352
  • [24] High EZH2 Protein Expression Is Associated with Inferior Survival in Patients with Multiple Myeloma
    Tremblay-LeMay, Rosemarie
    Pourabdollah, Maryam
    Rastgoo, Nasrin
    Chang, Hong
    LABORATORY INVESTIGATION, 2018, 98 : 560 - 561
  • [25] Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents
    Nucci, Marcio
    Anaissie, Elias
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (08) : 1211 - 1225
  • [26] Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment
    Sonneveld, P
    Segeren, CM
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) : 9 - 18
  • [27] EZH2 Inhibition and the Combination with Proteasome Inhibition Are Novel Potential Strategies for the Treatment of Multiple Myeloma
    Rizq, Ola
    Mimura, Naoya
    Koide, Shuhei
    Ma, Anqi
    Jin, Jian
    Iseki, Tohru
    Nakaseko, Chiaki
    Iwama, Atsushi
    BLOOD, 2014, 124 (21)
  • [28] Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours
    El-Helw, L
    Coleman, RE
    CANCER TREATMENT REVIEWS, 2005, 31 (03) : 197 - 209
  • [29] STUDIES OF HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA (MM)
    PERREN, TJ
    SELBY, PJ
    MBIDDE, RK
    MALPAS, JS
    MCELWAIN, TJ
    BRITISH JOURNAL OF CANCER, 1986, 54 (01) : 207 - 207
  • [30] DOUBLE HIGH-DOSE CHEMOTHERAPY BY THIOTEPA TO TREAT POOR PROGNOSIS OSTEOSARCOMA
    Deparis, M.
    Gaspar, N.
    Brugieres, L.
    Minckes, O.
    Dufour, C.
    Valteau-Couanet, D.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 25 - 25
12345